PHLCX — PGIM Jennison Health Sciences Fund
Data updated: 2026-07-27
PHLCX — PGIM Jennison Health Sciences Fund. United States Large Cap Blend / Core Health Care Equity · $1.39B AUM. Holdings, fees, performance and SEC filings.
PHLCX Fund Overview
PHLCX — PGIM Jennison Health Sciences Fund is a US mutual fund managed by Prudential Sector Funds, Inc., categorised as United States Large Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Prudential Sector Funds, Inc.
- Category: United States Large Cap Blend / Core Health Care Equity
- Assets under management: $1.39B
- 1-year return: 30.0%
- Ticker: PHLCX
- SEC CIK: 0000352665
- SEC series ID: S000004380
- Share class ID: C000012123
PHLCX Holdings
Top 10 holdings of PGIM Jennison Health Sciences Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Eli Lilly & Company | 17.35% |
| Merck & Company, Inc. | 6.06% |
| Unitedhealth Group, Inc. | 5.87% |
| Thermo Fisher Scientific, Inc. | 4.56% |
| Argenx SE | 3.55% |
| Vertex Pharmaceuticals, Inc. | 3.37% |
| Danaher Corp. | 3.28% |
| Intuitive Surgical, Inc. | 3.07% |
| Lonza Group AG | 3.02% |
| Cvs Health Corp. | 2.52% |
PHLCX Portfolio Allocation
Asset-class allocation of PGIM Jennison Health Sciences Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 97.8% |
| Cash & Equivalents | 3.8% |
PHLCX Performance
Total returns for PHLCX (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -0.1% |
| 1 year | 30.0% |
| 3 years (annualised) | 11.4% |
| 5 years (annualised) | 5.6% |
PHLCX Risk Information
Risk metrics for PHLCX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 16.0%
PHLCX Costs and Fees
PHLCX costs about $197 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.97%
- Gross expense ratio: 1.97%
- Portfolio turnover: 81%
- Brokerage commissions: 6.92 bps of average net assets (SEC N-CEN)
PHLCX Cashflows
Over the 12 months to 2026-05, PGIM Jennison Health Sciences Fund had net outflows of $161.92M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-05 | −$24.47M |
| 2026-04 | −$19.95M |
| 2026-03 | −$19.65M |
| 2026-02 | −$14.99M |
| 2026-01 | −$17.15M |
| 2025-12 | $130.36M |
PHLCX Debt Constituents
No individual debt constituents are reported in PGIM Jennison Health Sciences Fund's latest SEC N-PORT filing.
PHLCX Prospectus and SEC Filings
Official PGIM Jennison Health Sciences Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2026-01-28
- Prospectus (485BPOS) — filed 2024-01-26
- Prospectus (485BPOS) — filed 2023-01-26
- Portfolio holdings (N-PORT) — filed 2026-07-27
- Portfolio holdings (N-PORT) — filed 2026-04-23
- Portfolio holdings (N-PORT) — filed 2026-01-28
- Annual census (N-CEN) — filed 2026-02-10
- Annual census (N-CEN) — filed 2025-02-11
Related Funds
Other United States Large Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.